SEC Form 4 · accession 0001209191-15-062176
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Jul 22, 2015
Accepted (ET)
Jul 23, 2015 · 4:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 22, 2015 | M | 10,400 | $35.64 | A | 355,684 | D | |
| Common StockF2,F3 | Jul 22, 2015 | S | 9,200 | $130.82 | D | 346,484 | D | |
| Common StockF3,F4 | Jul 22, 2015 | S | 1,200 | $131.68 | D | 345,284 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401(k) | |
| Common Stock | holding | — | — | — | 122,700 | I | Common Stock held in trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $35.64 | Jul 22, 2015 | M | 10,400 | D | — | Feb 1, 2016 | Common Stock | 10,400 | 281,600 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $130.82 (range $130.27 to $131.22).
- F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $131.68 (range $131.47 to $131.80).
- F5Fully vested.